Thermo Fisher Announce Early Termination of Waiting Period for Acquisition of Finesse Solutions
Thermo Fisher Scientific Inc. today announced that its pending acquisition of Finesse Solutions, Inc., a developer of scalable control automation systems and software for bioproduction, has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Thermo Fisher expects to complete the acquisition in the coming days.
Based in Santa Clara, California, Finesse Solutions is a leader in bioprocess management technology, generating approximately $50 million in revenue in 2016. Its proprietary Smart™ technology, which consists of sensors, controllers and software, is designed to optimize the bioproduction workflow. The business will be integrated into Thermo Fisher’s Life Sciences Solutions Segment. Terms of the transaction were not disclosed.
“Finesse Solutions has been a technology partner since 2013, and we are pleased to add their complementary capabilities to our leading bioproduction offering,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “Finesse Solutions has developed a universal control system that will combine seamlessly with our existing single-use technologies to strengthen our position in the high-growth bioproduction market.”
“We are excited to join Thermo Fisher Scientific, and look forward to leveraging the company’s strength and reach to accelerate the development and commercialization of our Smart technology platform,” added Dr. Barbara Paldus, CEO and co-founder of Finesse Solutions.
This article has been republished from materials provided by Thermo Fisher. Note: material may have been edited for length and content. For further information, please contact the cited source.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019